Cargando…

Monoclonal antibody therapies against SARS-CoV-2

Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs and their effect as therapeutics in the pandemic, including structural classification, outcomes in clinical trials that led t...

Descripción completa

Detalles Bibliográficos
Autores principales: Focosi, Daniele, McConnell, Scott, Casadevall, Arturo, Cappello, Emiliano, Valdiserra, Giulia, Tuccori, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255948/
https://www.ncbi.nlm.nih.gov/pubmed/35803289
http://dx.doi.org/10.1016/S1473-3099(22)00311-5
_version_ 1784741016745541632
author Focosi, Daniele
McConnell, Scott
Casadevall, Arturo
Cappello, Emiliano
Valdiserra, Giulia
Tuccori, Marco
author_facet Focosi, Daniele
McConnell, Scott
Casadevall, Arturo
Cappello, Emiliano
Valdiserra, Giulia
Tuccori, Marco
author_sort Focosi, Daniele
collection PubMed
description Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs and their effect as therapeutics in the pandemic, including structural classification, outcomes in clinical trials that led to the authorisation of mAbs, and baseline and treatment-emergent immune escape. We show how the omicron (B.1.1.529) variant of concern has reset treatment strategies so far, discuss future developments that could lead to improved outcomes, and report the intrinsic limitations of using mAbs as therapeutic agents.
format Online
Article
Text
id pubmed-9255948
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-92559482022-07-06 Monoclonal antibody therapies against SARS-CoV-2 Focosi, Daniele McConnell, Scott Casadevall, Arturo Cappello, Emiliano Valdiserra, Giulia Tuccori, Marco Lancet Infect Dis Review Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs and their effect as therapeutics in the pandemic, including structural classification, outcomes in clinical trials that led to the authorisation of mAbs, and baseline and treatment-emergent immune escape. We show how the omicron (B.1.1.529) variant of concern has reset treatment strategies so far, discuss future developments that could lead to improved outcomes, and report the intrinsic limitations of using mAbs as therapeutic agents. Elsevier Ltd. 2022-11 2022-07-05 /pmc/articles/PMC9255948/ /pubmed/35803289 http://dx.doi.org/10.1016/S1473-3099(22)00311-5 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Focosi, Daniele
McConnell, Scott
Casadevall, Arturo
Cappello, Emiliano
Valdiserra, Giulia
Tuccori, Marco
Monoclonal antibody therapies against SARS-CoV-2
title Monoclonal antibody therapies against SARS-CoV-2
title_full Monoclonal antibody therapies against SARS-CoV-2
title_fullStr Monoclonal antibody therapies against SARS-CoV-2
title_full_unstemmed Monoclonal antibody therapies against SARS-CoV-2
title_short Monoclonal antibody therapies against SARS-CoV-2
title_sort monoclonal antibody therapies against sars-cov-2
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255948/
https://www.ncbi.nlm.nih.gov/pubmed/35803289
http://dx.doi.org/10.1016/S1473-3099(22)00311-5
work_keys_str_mv AT focosidaniele monoclonalantibodytherapiesagainstsarscov2
AT mcconnellscott monoclonalantibodytherapiesagainstsarscov2
AT casadevallarturo monoclonalantibodytherapiesagainstsarscov2
AT cappelloemiliano monoclonalantibodytherapiesagainstsarscov2
AT valdiserragiulia monoclonalantibodytherapiesagainstsarscov2
AT tuccorimarco monoclonalantibodytherapiesagainstsarscov2